March 10, 2024
Loading...
You are here:  Home  >  'FDA'  -  Page 12
Latest

Amgen asks FDA to approve biosimilar drug

By   /  Wednesday, November 25th, 2015  /  Health Care & Life Science, Latest news, Top Stories  /  Comments Off on Amgen asks FDA to approve biosimilar drug

Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →

Latest

Sientra collapse doomed execs

By   /  Friday, November 20th, 2015  /  Health Care & Life Science, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Sientra collapse doomed execs

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Goleta breast implant maker Sientra shakes up C-Suite

By   /  Thursday, November 12th, 2015  /  Health Care & Life Science, Latest news, South Coast, Top Stories, Tri-County Public Companies  /  Comments Off on Goleta breast implant maker Sientra shakes up C-Suite

  The writing was on the wall at Sientra. On Nov. 12, the company’s top executives took the fall. The embattled Goleta-based breast implant manufacturer cleaned house Thursday afternoon. Sientra founder and CEO Hani Zeini stepped down as CEO and he will be replaced by industry veteran Jeffrey Nugent. Nicholas Simon also resigned as chairman Read More →

Latest

FDA to review Amgen’s new kidney disease dug

By   /  Friday, November 6th, 2015  /  East Ventura County, Health Care & Life Science, Latest news  /  Comments Off on FDA to review Amgen’s new kidney disease dug

Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →

Latest

Goleta’s Sientra reassures investors, surgeons

By   /  Friday, November 6th, 2015  /  Health Care & Life Science, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Goleta’s Sientra reassures investors, surgeons

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Sientra sends letter to surgeons about breast implant production

By   /  Friday, October 30th, 2015  /  Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Sientra sends letter to surgeons about breast implant production

  Sientra CEO Hani Zeini issued a letter to plastic surgeons Oct. 30 outlining what the Goleta-based breast implant manufacturer needs to do to restart production at its plant in Brazil. Zeini also implied in the letter that the Food and Drug Administration is going to make a decision regarding Sientra products, which is something Read More →

Latest

FDA OKs Amgen skin cancer drug Imlygic

By   /  Tuesday, October 27th, 2015  /  Health Care & Life Science, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on FDA OKs Amgen skin cancer drug Imlygic

The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →